Malignant lymphoma after diphenylhydantoin (dilantin) therapy

Cancer

Volumn 36, Issue 4, 1975, Pages 1359-1362

  Li, Frederick P ^a   Willard, Douglas R ^b   Goodman, Robert ^c   Vawter, Gordon ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHENYTOIN;

ADVERSE DRUG REACTION; CANCER; CARCINOGENESIS; ETIOLOGY; HODGKIN DISEASE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOHISTIOCYTOSIS; LYMPHOMA; ORAL DRUG ADMINISTRATION; STATISTICS;

ADULT; FEMALE; HODGKIN DISEASE; HUMAN; LYMPHOMA; MALE; MIDDLE AGE; PHENYTOIN;

EID: 0016840302     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(197510)36:4<1359::AID-CNCR2820360426>3.0.CO;2-L     Document Type: Article

References (29)

1. Malignant lymphoma associated with hydantoin drugs
2. Le sostanze di idantoina come possibili cause del linfoma maligno
3. Pseudolymphoma induced by diphenylhydantoin
4. Are anticonvulsants oncogenic?
5. Lymphoma or drug reaction occurring during hydantoin therapy for epilepsy
6. Transplacental carcinogenesis
7. Hodgkin's disease in childhood—An epidemiologic study
8. Hydantoin‐induced pseudo‐pseudolymphoma
9. Essential relationship between the lymphoid system, immunity, and malignancy
10. Vaginal cancer after maternal treatment with synthetic estrogens
11. Immunological abnormalities and hydantoins
12. Non‐Hodgkin's lymphoma in childhood—Epidemiologic features
13. Diphenylhydantoin‐induced hypersensitivity reaction
14. Risk of cancer in renal‐transplant recipients
15. The development of Hodgkin's disease and lymphoma during anticonvulsant therapy
16. Role of immunologic disturbance in human oncogenesis: some facts and fancies
17. Is phenytoin carcinogenic?
18. Effect of Dilantin in mice
19. Immunologic characterization of human malignant lymphomas
20. Immunoblastic lymphadenopathy
21. Transplacental chemical carcinogenesis in man
22. Diphenylhydantoin and selected congenital malformations
23. Phenytoin and the pesudolymphoma syndrome
24. Malignant lymphogranulomatosis and anticonvulsant therapy
25. Lymphadenopathy induced by anticonvulsant drugs and mimicking clinically and pathologically malignant lymphomas
26. Malignant lymphomas following allogenic disease—transition from an immunological to a neoplastic disorder
27. Depression of immunological function in patients treated with phenytoin sodium (sodium diphenylhydantoin)
28. Lymphoma and anticonvulsive therapy
29. Immunodeficiency disease and malignancy